Incyte began its search in the mid-Atlantic area for a facility in September 2001, hoping to make the move the following spring. "Delaware's ability to provide readily available lab space and our significant research and development workforce played key roles in attracting Incyte to Delaware," Delaware Economic Development Office director John D. Wik tells GlobeSt.com. "Incyte's decision to locate in Delaware will greatly enhance our state's biotechnology resources. In addition, the research and development to be conducted at the company's new location will significantly boost Delaware's development as a global hub for biotechnology." The Stine-Haskell complex of buildings, which was dedicated half a century ago, sits on 530-acres.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
